Skip to main content
Navigate Up
Sign In
 

Dr. Daniel Pollyea Reports the Latest Results from a New Leukemia Drug


A phase I trial of the first drug designed to inhibit the cancer-causing activity of a mutated enzyme known as isocitrate dehydrogenase (IDH) 1, which is involved in cell metabolism, has shown clinical activity in patients with advanced acute myeloid leukemia (AML) with the IDH1 mutation.

Read More -->